

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner

v.

ALCON RESEARCH, LTD.,
Patent Owner

Case IPR2017-01053
Patent 8,268,299

ALCON RESEARCH, LTD.'S FOURTH UPDATED EXHIBIT LIST

| <i>Alcon Exhibit No.</i> | <i>Description</i> |
|---------------------------------|---|
| 2001 | Declaration of Adam L. Perlman in Support of Motion for <i>Pro Hac Vice</i> Admission Pursuant to 37 C.F.R. § 42.10(c) |
| 2002 | Declaration of Alexander S. Zolan in Support of Motion for <i>Pro Hac Vice</i> Admission Pursuant to 37 C.F.R. § 42.10(c) |
| 2003 | Declaration of Christopher J. Mandernach in Support of Motion for <i>Pro Hac Vice</i> Admission Pursuant to 37 C.F.R. § 42.10(c) |
| 2004 | Center for Drug Evaluation and Research, Medical Review, NDA No. 21-994. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000TOC.cfm |
| 2005 | United States Patent Application Publication No. 2007/0212420 A1 |
| 2006 | Declaration of Bhagwati P. Kabra, Ph.D. |
| 2007 | Declaration of Stephen Shannon, MBA, Ph.D. |
| 2008 | Alcon Laboratory Notebook No. 11118, pp. 77–82 |
| 2009 | Alcon Laboratory Notebook No. 11781, pp.19–21 |
| 2010 | Alcon Laboratory Notebook No. 10545, p. 51 |
| 2011 | Alcon Laboratory Notebook No. 10750, p. 81 |
| 2012 | Alcon Laboratory Notebook No. 11068, pp. 17–24 |
| 2013 | Alcon Laboratory Notebook No. 9988, p. 87 |
| 2014 | Alcon Laboratory Notebook No. 13160, p. 66 |
| 2015 | Alcon Laboratory Notebook No. 13292, pp. 38–39 |
| 2016 | Alcon Laboratory Notebook No. 11781, pp. 81–83 |
| 2017 | Adjunctive Pages to Alcon Laboratory Notebook No. 11781, pp. 81–83 |
| 2018 | Alcon Laboratory Notebook No. 10750, p. 19 |
| 2019 | Alcon Laboratory Notebook No. 10545, p. 41 |
| 2020 | Alcon Laboratory Notebook No. 10750, p. 21 |
| 2021 | Alcon Laboratory Notebook No. 12586, p. 63 |
| 2022 | Alcon Laboratory Notebook No. 12034, p. 91 |
| 2023 | Declaration of Soumyajit Majumdar, Ph.D. |
| 2024 | Curriculum Vitae of Soumyajit Majumdar, Ph.D |
| 2025 | Declaration of George Zhanel, Ph.D |
| 2026 | Curriculum Vitae of George Zhanel, Ph.D |
| 2027 | Declaration of Richard K. Parrish, II, M.D. |
| 2028 | Curriculum Vitae of Richard K. Parrish, II, M.D. |
| 2029 | Declaration of Henry Grabowski, Ph.D. |
| 2030 | Curriculum Vitae of Henry Grabowski, Ph.D. |

| | |
|------|---|
| 2031 | The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals (13th ed. 2001), Merck Research Laboratories, 1810 |
| 2032 | 53 Fed. Reg. 7076 (Mar. 4, 1988) |
| 2033 | U.S. Pharmacopeia 23 (1995) |
| 2034 | Remington: The Science and Practice of Pharmacy (20th ed. 2000) |
| 2035 | Final Report on the Safety Assessment of Polyquaternium-10, <i>7 J. of the Am. College of Toxicology</i> 347 (1988) |
| 2036 | United States Patent No. 5,336,508 |
| 2037 | United States Patent No. 5,393,491 |
| 2038 | United States Patent No. 5,741,817 |
| 2039 | United States Patent No. 6,872,705 |
| 2040 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs |
| 2041 | TRAVATAN Z [®] Wholesale Dollar Sales |
| 2042 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Share of Wholesale Dollar Sales |
| 2043 | Number of Prescriptions for TRAVATAN Z [®] |
| 2044 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Share of Prescriptions |
| 2045 | Number of New Prescriptions for TRAVATAN Z [®] |
| 2046 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Share of New Prescriptions |
| 2047 | TRAVATAN Z [®] Unit Sales |
| 2048 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Share of Unit Sales |
| 2049 | TRAVATAN Z [®] , TRAVATAN [®] , and LUMIGAN [®] , Cumulative Wholesale Dollar Sales |
| 2050 | Number of Prescriptions for TRAVATAN [®] |
| 2051 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Share of Voice Excluding Retail Value of Samples |
| 2052 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Share of Voice Including Retail Value of Samples |
| 2053 | TRAVATAN Z [®] , TRAVATAN [®] , and LUMIGAN [®] , Marketing-to-Sales Ratio Excluding Retail Value of Samples |
| 2054 | TRAVATAN Z [®] , TRAVATAN [®] , and LUMIGAN [®] , Promotional Spending Excluding Retail Value of Samples |
| 2055 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Formulary Placement for Commercial Plans 2017–2018 |
| 2056 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Formulary Placement for Commercial Plans 2017–2018 |

| | |
|------|--|
| 2057 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Formulary Placement for Medicare Plans 2017–2018 |
| 2058 | TRAVATAN Z [®] and Other Prostaglandin Analog Drugs, Formulary Placement for Medicare Plans 2017–2018 |
| 2059 | “Bibliography of Published Papers and Presentations Using QuintilesIMS Information,” QuintilesIMS Institute, May 2017 |
| 2060 | U.S. Food and Drug Administration, TRAVATAN Z [®] NDA Approval Letter, September 21, 2006 |
| 2061 | Alcon, Inc., Form 20-F 2006 |
| 2062 | U.S. Food and Drug Administration, TRAVATAN Z [®] Label, July 2010 |
| 2063 | Sucampo Pharmaceuticals Inc., Form 10-K 2014 |
| 2064 | Regnier, S. A. and D. B. Ridley, 2015, “Market Watch: Forecasting Market Share in the US Pharmaceutical Market,” <i>Nature Reviews Drug Discovery</i> , Vol. 14, No. 9, pp. 594–595 |
| 2065 | Kalyanaram, G., 2008, “The Order of Entry Effect in Prescription (Rx) and Over-the-Counter (OTC) Pharmaceutical Drugs,” <i>International Journal of Pharmaceutical and Healthcare Marketing</i> , Vol. 2, No. 1, pp. 35–46 |
| 2066 | Berndt, E. R., et al., 1995, “Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market,” <i>The American Economic Review</i> , Vol. 85, No. 2, pp. 100–105 |
| 2067 | Berndt, E. R., et al., 2002, “An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts,” <i>The Journal of Mental Health Policy and Economics</i> , Vol. 5, pp. 3–19 |
| 2068 | Schmalensee, R., 1982, “Product Differentiation Advantages of Pioneering Brands,” <i>The American Economic Review</i> , Vol. 72, No. 3, pp. 349–365 |
| 2069 | Azoulay, P., 2002, “Do Pharmaceutical Sales Respond to Scientific Evidence?” <i>Journal of Economics & Management Strategy</i> , Vol. 11, No. 4, pp. 551–594 |
| 2070 | Iizuka, T., 2004, “What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs?” <i>The Journal of Industrial Economics</i> , Vol. 52, No. 3, pp. 349–379 |
| 2071 | Leffler, K. B., 1981, “Persuasion or Information? The Economics of Prescription Drug Advertising,” <i>Journal of Law and Economics</i> , Vol. 24, No. 1, pp. 45–74 |
| 2072 | Venkataraman, S. and S. Stremersch, 2007, “The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link?” <i>Management Science</i> , Vol. 53, No. 11, pp. 1688–1701 |

| | |
|------|--|
| 2073 | Berndt, E. R., 2001, “The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?” <i>Health Affairs</i> , Vol. 20, No. 2, pp. 100–114 |
| 2074 | Berndt, E. R., 2002, “Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price,” <i>Journal of Economic Perspectives</i> , Vol. 16, No. 4, pp. 45–66 |
| 2075 | Coscelli, A. and M. Shum, 2004, “An Empirical Model of Learning and Patient Spillovers in New Drug Entry,” <i>Journal of Econometrics</i> , Vol. 122, pp. 213–246 |
| 2076 | Lakdawalla, D. and T. Philipson, 2012, “Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets,” <i>Journal of Law and Economics</i> , Vol. 55, No. 1, pp. 151–187 |
| 2077 | Ross, J. S. and A. S. Kesselheim, 2013, “Prescription-Drug Coupons—No Such Thing as a Free Lunch,” <i>The New England Journal of Medicine</i> , Vol. 369, No. 13, pp. 1188–1189 |
| 2078 | “Prescription Drug Discount Coupons: Implications for Public and Commercial Health Care Plans,” Congressional Research Service, November 5, 2015, available at https://www.everycrsreport.com/files/20151105_R44264_cc230c6ca7301b5df95d1210de9d33ca46c9b64d.pdf |
| 2079 | “Prescription Drug Discount Coupons and Patient Assistance Programs (PAPs),” Congressional Research Service, June 15, 2017, available at https://www.everycrsreport.com/files/20170615_R44264_1620b32a24a5e7e0bd6150be54c139fc134c4ab2.pdf |
| 2080 | Starner, C., et al., 2014, “Specialty Drug Coupons Lower Out-of-Pocket Costs and May Improve Adherence at the Risk of Increasing Premiums,” <i>Health Affairs</i> , Vol. 33, No. 10, pp. 1761–1769 |
| 2081 | Shrank, W. H., et al., 2010, “The Epidemiology of Prescriptions Abandoned at the Pharmacy,” <i>Annals of Internal Medicine</i> , Vol. 153, No. 10, pp. 633–640, W-212–213 |
| 2082 | Tenaglia, M., 2012, “Copay Cards and Coupons: Letting the Facts Get in the Way,” PharmExec.com, available at http://www.pharmexec.com/copay-cards-and-coupons-letting-facts-get-way?id=&sk=&date=&%0A%09%09%09&pageID=2 |
| 2083 | “The Use of Medicines in the United States: Review of 2011,” IMS Institute for Healthcare Informatics, April 2012 |
| 2084 | PSKW Special Sponsored Section, 2016, “State of the Art: Highlights from CBI’s 2016 Formulary, Co-Pay and Access Summit,” <i>Pharmaceutical Executive</i> , Vol. 36, No. 6, pp. 14–15 |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.